Endoscopic evaluation of etodolac efficacy and tolerance ın patients of spondylosis - This open, non-comparative study was designed to investigate the clinical efficacy and tolerance of etodolac by endoscopic evaluation in primary spondylosis patients. 20 patients (3 males-17 females) with cervical and/or lumbar spondylosis, without any gastrointestinal complaint and active ulcer finding by endoscopic evaluation we included in this study. They received 2x300 mg daily dose of etodolac. Following parameters were included in the evaluation before treatment and on the 30th day of treatment: pain in the resting, with pression and motion by visual analogue scale; lordosis, functional scoliosis, paravertebral spasm and range of motion by simple scale; laboratory findings, blood pressure. Patients were evaluated by oesophagogastroduodenoscopie before and after treatment.
Etodolac proved statistically effective in relieving clinical symptomps and functional status, without an effect on laboratory findings and blood pressure. 25 % (5 cases) of patients had slight transient side effects, none of them stopped treatment. 75 % of all patients were assessed as grade 0,10 % as grade 1,15 % as grade 2 by endoscopic evaluation before etodolac treatment. Following treatment, 17 patients showed no difference in endoscopic evaluation, in contrast 1 case transformed from garde 0 to grade 1,1 case from grade 0 to grade 4 and 1 case from grade 1 to grade 2. The results from this study indicate that etodolac is of high clinical efficacy and safe in treatment of spondylosis.